In NB, the strong combined effect we observed with CYC065 in combination with temozolomide, which is used for therapy-resistant NB, supports the addition of CYC065 as a means for selectively targeting MYCN-driven adrenergic identity. The gene discussed is MYCN; the disease is neuroblastoma.